Published online before print March 20, 2003, doi: 10.1161/01.ATV.0000067935.02679.B0
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2003 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Identification of Immune Responses Against Aldehyde-Modified Peptide Sequences in ApoB Associated With Cardiovascular Disease
From the Departments of Medicine (G.N.F., B.H., G.B., R.A., M.A., J.N.) and Community Medicine (B.H.), Malmö University Hospital, Lund University, Sweden; Department of Biomedical Laboratory Science (G.N.F.), Malmö University, Sweden; and Atherosclerosis Research Center (B.C., K.-Y.C., P.K.S.), Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, Calif.
Correspondence to Gunilla Nordin Fredrikson, Wallenberg Laboratory, 1st Floor, Malmö University Hospital, S-205 02 Malmö, Sweden. E-mail Gunilla.Nordin_Fredrikson{at}medforsk.mas.lu.se
Objective— Atherosclerosis is associated with an immune response against oxidized LDL, which modulates the progression of the disease process.
Methods and Results— Using a library of polypeptides covering the complete sequence of apoB-100, the only major protein of LDL, we have identified over 100 different human antibodies reacting against aldehyde-modified apoB-100 sequences. IgM antibody titer levels decreased with age and were associated with the intima-media thickness of the carotid artery in subjects younger than 60 years. There were also inverse associations between IgM levels and oxidized LDL in plasma. In prospective clinical studies, antibody levels against several aldehyde-modified apoB-100 sites were associated with cardiovascular disease in this age group. Whether this immune response is adaptive (protective) or maladaptive (causal) in atherosclerosis requires further investigation.
Conclusions— We have characterized a large number of epitopes within the apoB-100 component of oxidized LDL that provoke an immune response in humans. These findings will make it possible to study the role of immune responses against specific sites in oxidized LDL and to determine whether these immune responses influence the risk for future cardiac events.
Key Words: apolipoproteins • atherosclerosis • cardiovascular diseases • immune responses • peptide sequences
This article has been cited by other articles:
 |
|
 |
|
  P. Sjogren, G. N. Fredrikson, A. Samnegard, C.-G. Ericsson, J. Ohrvik, R. M. Fisher, J. Nilsson, and A. Hamsten High plasma concentrations of autoantibodies against native peptide 210 of apoB-100 are related to less coronary atherosclerosis and lower risk of myocardial infarction Eur. Heart J., September 2, 2008; 29(18): 2218 - 2226. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Schiopu, B. Frendeus, B. Jansson, I. Soderberg, I. Ljungcrantz, Z. Araya, P. K. Shah, R. Carlsson, J. Nilsson, and G. N. Fredrikson Recombinant Antibodies to an Oxidized Low-Density Lipoprotein Epitope Induce Rapid Regression of Atherosclerosis in Apobec-1 / /Low-Density Lipoprotein Receptor / Mice J. Am. Coll. Cardiol., December 11, 2007; 50(24): 2313 - 2318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. N. Fredrikson, B. Hedblad, G. Berglund, R. Alm, J.-A. Nilsson, A. Schiopu, P. K. Shah, and J. Nilsson Association Between IgM Against an Aldehyde-Modified Peptide in Apolipoprotein B-100 and Progression of Carotid Disease Stroke, May 1, 2007; 38(5): 1495 - 1500. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. N. Fredrikson, G. Berglund, R. Alm, J.-A. Nilsson, P. K. Shah, and J. Nilsson Identification of autoantibodies in human plasma recognizing an apoB-100 LDL receptor binding site peptide J. Lipid Res., September 1, 2006; 47(9): 2049 - 2054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tedgui and Z. Mallat Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways Physiol Rev, April 1, 2006; 86(2): 515 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Shinohara, S. Kawashima, T. Yamashita, T. Takaya, R. Toh, T. Ishida, T. Ueyama, N. Inoue, K.-i. Hirata, and M. Yokoyama Xenogenic smooth muscle cell immunization reduces neointimal formation in balloon-injured rabbit carotid arteries Cardiovasc Res, November 1, 2005; 68(2): 249 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Goncalves, M.-L. M. Gronholdt, I. Soderberg, M. P.S. Ares, B. G. Nordestgaard, J. F. Bentzon, G. N. Fredrikson, and J. Nilsson Humoral Immune Response Against Defined Oxidized Low-Density Lipoprotein Antigens Reflects Structure and Disease Activity of Carotid Plaques Arterioscler. Thromb. Vasc. Biol., June 1, 2005; 25(6): 1250 - 1255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Nilsson, G. K. Hansson, and P. K. Shah Immunomodulation of Atherosclerosis: Implications for Vaccine Development Arterioscler. Thromb. Vasc. Biol., January 1, 2005; 25(1): 18 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Gershagen and S. Janciauskiene ELISA for Specific Detection of PiZ-Related {alpha}1-Antitrypsin Deficiency Clin. Chem., December 1, 2004; 50(12): 2407 - 2410. [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. Michelsen, T. M. Doherty, P. K. Shah, and M. Arditi TLR Signaling: An Emerging Bridge from Innate Immunity to Atherogenesis J. Immunol., November 15, 2004; 173(10): 5901 - 5907. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Schiopu, J. Bengtsson, I. Soderberg, S. Janciauskiene, S. Lindgren, M. P.S. Ares, P. K. Shah, R. Carlsson, J. Nilsson, and G. N. Fredrikson Recombinant Human Antibodies Against Aldehyde-Modified Apolipoprotein B-100 Peptide Sequences Inhibit Atherosclerosis Circulation, October 5, 2004; 110(14): 2047 - 2052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Stocker and J. F. Keaney Jr. Role of Oxidative Modifications in Atherosclerosis Physiol Rev, October 1, 2004; 84(4): 1381 - 1478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. N. Fredrikson, I. Soderberg, M. Lindholm, P. Dimayuga, K.-Y. Chyu, P. K. Shah, and J. Nilsson Inhibition of Atherosclerosis in ApoE-Null Mice by Immunization with ApoB-100 Peptide Sequences Arterioscler. Thromb. Vasc. Biol., May 1, 2003; 23(5): 879 - 884. [Abstract] [Full Text] [PDF]
|
|